Promotional materials claiming that visual fields were unchanged or improved in 95% of Alphagan (brimonide tartrate ophthalmic solution) treated patients are "inconsistent with the approved product labeling and constitutes an unapproved new use," FDA says in an April 15 letter. "Alphagan is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, not for the preservation of visual fields." In addition, the Allergan tagline "The Drop Without the Downside" is misleading, FDA says, because it implies that the product does not have side effects. "However, Alphagan has numerous precautions, adverse reactions and contraindications in its approved product labeling such as the precaution regarding the potential for a decrease in mental alertness for patients who may engage in hazardous activities," the agency notes
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth